TCR² Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Company initiated Phase 1/2 clinical trial for TC-110, its lead hematological malignancy candidate Interim update from Phase 1 portion of TC-210 Phase 1/2 trial anticipated in 2Q20 and Phase 1/2 trial of TC-110 in 2H20 TCR2 manufacturing suite fully …